查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010005

基因组学市场：按产品类型、技术、应用和最终用户分類的全球市场预测 - 2026-2032 年

Genomics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因组学市场价值将达到 571.5 亿美元，到 2026 年将成长到 626 亿美元，到 2032 年将达到 1,122.6 亿美元，复合年增长率为 10.12%。

主要市场统计数据
基准年 2025 571.5亿美元
预计年份：2026年 626亿美元
预测年份 2032 1122.6亿美元
复合年增长率 (%) 10.12%

为研究、临床和商业相关人员制定策略指南，以建立当前的基因组学趋势、技术考量和关键决策。

随着技术创新、跨领域合作以及监管预期不断变化，基因组学领域正经历快速发展，并重塑研究机构、医疗服务提供者和商业公司的策略重点。本文概述了高阶主管、研发负责人和采购团队在评估技术应用、合作机会和资本配置时应考虑的关键因素。此外，本文也将这一主题置于转化科学、供应链韧性以及治疗方法和诊断领域整体精准医疗日益增长的需求等更广泛的背景下进行探讨。

技术突破、不断演变的经营模式以及日益增长的监管期望如何重塑基因组学领域的竞争格局和营运重点。

基因组学格局正因技术成熟度、经营模式转变和新兴政策趋势的相互作用而发生变革，由此产生的结构性变化亟需对现有策略进行重新评估。高通量定序和单细胞分析技术的进步降低了产生复杂资料集的门槛，从而促进了从孤立实验向整合多体学专案的转变。这种转变有利于那些能够将分析深度与稳健的资料管理和解读框架结合的机构，使其不仅在处理能力方面脱颖而出，更在可操作的洞见方面实现差异化。

评估 2025 年关税措施对基因组学企业的筹资策略、供应链弹性计画和供应商风险分配的影响。

关税和贸易限制等措施的实施会对基因组学生态系统产生多方面的影响，可能波及供应商关係、采购决策以及实验室运作的成本结构。 2025年实施的关税促使采购团队加快重新评估其供应商组合、实现供应商多元化并寻找替代供应商，以确保关键设备和耗材的持续供应。这种转变使得采购团队更加重视那些拥有稳健製造地和透明关税减免策略的供应商。

透过对产品、应用、最终用户和技术等方面进行全面細項分析，指导有针对性的研发、商业化和服务策略。

了解市场区隔对于建立整个基因组学领域的产品开发、商业策略和服务交付模式至关重要。依产品类型分析市场，可以发现微阵列、PCR、试剂和耗材、定序服务以及定序系统等细分市场。微阵列类别进一步细分为基因表现晶片和SNP基因型鉴定晶片，而PCR则分为数位PCR和qPCR。试剂和耗材包括酵素和预混液、样品製备盒、探针和引子。定序服务包括次世代定序服务和Sanger定序服务。定序系统进一步细分为NGS平台和Sanger测序仪。这种以产品为中心的观点突显了创新发生的领域，以及传统平台生命週期压力可能推动的再投资或迁移。

区域情报观点，将美洲、欧洲、中东和非洲以及亚太市场的采用驱动因素、监管多样性和伙伴关係机会连结起来。

区域趋势在决定整个基因组学生态系统的应用模式、监管路径和伙伴关係方面发挥着至关重要的作用。在美洲，大规模的集中，催生了对先进定序和精准诊断的需求，同时也促进了商业开发商和临床采用者之间的密切合作。这种环境加速了从研究创新到临床检验试验和商业部署的转化。

以平台整合、服务扩展和策略伙伴关係为中心的供应商策略如何重新定义竞争优势和客户维繫。

企业层面的措施正在重塑竞争格局，主要企业正投资于平台整合、服务多元化和策略伙伴关係，以实现超越单一产品销售的价值。那些将仪器创新与强大的试剂组合和扩充性的服务交付相结合的企业，更有能力提供满足端到端客户需求的整合解决方案。此外，对软体、数据分析和云端解读服务的投资，正在创造新的收入来源，并透过持续的服务模式增强客户留存率。

实际可行的措施，使高阶主管能够加强供应链韧性，实现平台互通性，并提供以结果为导向的服务，从而加速采用。

产业领导者必须采取一系列切实可行的应对措施，重点关注供应链韧性、平台互通性和以价值主导的客户参与，以应对不断变化的基因组学格局。首先，各组织应优先考虑关键耗材的双重采购和本地库存策略，以减轻贸易政策波动和物流中断的影响。与主要供应商签订多年期合约并投资于供应商可视性工具，可以降低风险并提高营运的可预测性。

采用严谨的多源调查方法，结合关键相关人员的访谈、技术文献综述和分析框架，来检验趋势和策略意义。

为确保全面平衡的观点，本研究采用了多方面的调查方法，结合了关键相关人员的访谈、技术文献综述以及对产品和监管趋势的系统分析。主要活动包括与各仪器和试剂供应商的研发经理、临床实验室主任、采购专家和销售经理进行对话。这些对话旨在深入了解营运挑战、产品应用驱动因素以及应对不断变化的政策和供应链环境的策略性倡议。

一项结论性的综合分析强调了适应性、技术整合和管治是不断发展的基因组学生态系统中持续成功的关键因素。

总之，该报告重申，基因组学正处于一个转折点，技术能力、商业性创新和监管控制的交汇点将决定未来的赢家和输家。那些将投资集中于互通平台、弹性供应链和以结果为导向的服务的机构，将建立可持续的竞争优势。此外，积极应对监管和数据管治问题，将加速检查室成果向临床和商业性应用的转化。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 基因组学市场：依产品类型划分

  • 微阵列
    • 基因表现晶片
    • SNP基因型鉴定晶片
  • PCR
    • 数位PCR
    • qPCR
  • 试剂和耗材
    • 酵素和母料
    • 样品製备工具包
    • 探针和引子
  • 定序服务
    • NGS服务
    • 桑格定序服务
  • 定序系统
    • NGS平台
    • 桑格定序仪

第九章：基因组学市场：依技术划分

  • 阵列技术
    • 利用微阵列进行基因表现分析
    • SNP基因型鉴定晶片
  • DNA定序
    • 次世代定序
    • 桑格定序
  • PCR技术
    • 数位PCR
    • qPCR
  • RNA定序
    • 批量RNA定序
    • 单细胞RNA定序

第十章 基因组学市场：依应用领域划分

  • 农业
    • 动物基因体学
    • 作物基因组学
  • 诊断
    • 癌症基因体学
    • 基因检测
    • 传染病检查
  • 药物发现和药物开发
    • 生物标记发现
    • 目标识别
  • 个人化医疗
    • 伴随诊断
    • 精准治疗

第十一章 基因组学市场：依最终用户划分

  • 学术和政府机构
  • 私人研究机构
  • 医院和诊所
  • 製药和生物技术公司

第十二章 基因组学市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 基因组学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 基因组学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基因组学市场

第十六章：中国基因组学市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Azenta, Inc.
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Color Health, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-434CCDA04CD1

The Genomics Market was valued at USD 57.15 billion in 2025 and is projected to grow to USD 62.60 billion in 2026, with a CAGR of 10.12%, reaching USD 112.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 57.15 billion
Estimated Year [2026] USD 62.60 billion
Forecast Year [2032] USD 112.26 billion
CAGR (%) 10.12%

A strategic orientation that frames current genomics trends, technology considerations, and critical decisions for research, clinical, and commercial stakeholders

The landscape of genomics continues to evolve rapidly as technological innovation, cross-sector collaboration, and shifting regulatory expectations reshape strategic priorities for research institutions, healthcare providers, and commercial enterprises. This introduction synthesizes the principal drivers that executives, R&D leaders, and procurement teams must consider when evaluating technology adoption, partnership opportunities, and capital allocation. It situates the topic within the broader context of translational science, supply chain resilience, and the intensifying demand for precision approaches across therapeutics and diagnostics.

Emerging sequencing platforms, refinements in PCR modalities, and innovations in microarray design are unlocking new experimental capabilities while simultaneously altering vendor competition and service models. At the same time, applications spanning agriculture to personalized medicine are increasing the number of endpoints and data types that organizations must manage. Consequently, decisions about technology investments and outsourcing relationships are informed not only by instrument performance and reagent quality, but also by integration with bioinformatic pipelines, scalability of sample throughput, and long-term consumables availability.

Against this backdrop, stakeholders must weigh near-term operational needs against longer-term strategic objectives. This report's opening section frames the critical questions: how to prioritize platform selection in the face of heterogeneous use cases, how to mitigate supply and regulatory risks, and how to translate incremental technical advantages into measurable clinical or commercial value. The objective is to orient readers to the levers that will most significantly influence outcomes across research, clinical, and commercial settings.

How converging technology breakthroughs, evolving commercial models, and rising regulatory expectations are reshaping competitive dynamics and operational priorities in genomics

The genomics landscape is being transformed by an interplay of technological maturation, shifting business models, and emergent policy dynamics, producing structural shifts that require recalibrated strategies. Advances in high-throughput sequencing and single-cell capabilities have reduced barriers to generating complex datasets, which in turn is catalyzing a transition from siloed experiments to integrative multi-omic programs. This shift favors organizations that can combine analytical depth with robust data management and interpretation frameworks, thereby creating differentiation through actionable insights rather than raw throughput alone.

Concurrently, the commoditization of certain hardware components and the rise of reagent-focused business models are altering vendor economics and accelerating consolidation in segments where scale matters most. Service providers are expanding offerings to include end-to-end solutions that encompass sample logistics, sequencing, data processing, and regulatory support, thereby appealing to customers seeking simplicity and guaranteed quality. Meanwhile, increased interest in precision agriculture and infectious disease surveillance has broadened the range of end users and created adjacent markets where genomics capabilities can be deployed rapidly.

Finally, ethical and regulatory attention to data privacy, cross-border sample movement, and clinical validation is elevating governance as a competitive dimension. Organizations that proactively integrate compliance, transparent data stewardship, and validated workflows will be better positioned to capture long-term value. These transformative shifts are not isolated; they interact dynamically, meaning that technology choices, commercial partnerships, and compliance strategies must be aligned to navigate the new landscape effectively.

Assessment of how 2025 tariff measures have reshaped procurement strategies, supply chain resilience planning, and vendor risk allocation within genomics operations

The implementation of measures such as tariffs and trade restrictions can generate multi-layered effects on the genomics ecosystem, influencing supplier relationships, sourcing decisions, and cost structures for laboratory operations. Tariffs introduced in 2025 have had the effect of prompting procurement teams to reassess vendor portfolios, diversify sourcing, and accelerate qualification of alternative suppliers to ensure continuity of supply for critical instruments and consumables. This reorientation has placed a premium on suppliers with resilient manufacturing footprints and transparent tariff mitigation strategies.

In practice, organizations have responded by shifting some procurement toward domestically manufactured components or by increasing strategic inventory levels for high-use reagents and consumables. Contractual terms with service providers and instrument vendors have been renegotiated to account for extended lead times and to allocate risk related to cross-border logistics. Additionally, tariff-driven cost pressures have influenced capital expenditure planning, with some purchasers delaying non-essential instrument upgrades while prioritizing consumable availability for ongoing research and clinical workflows.

From a strategic perspective, the tariffs have underscored the importance of supply chain intelligence and scenario planning. Stakeholders are investing in deeper supplier audits, dual-sourcing strategies, and closer collaboration with manufacturers to map production capacity and identify chokepoints. In the medium term, these adaptations could encourage localized manufacturing expansion and longer-term contractual arrangements that provide visibility and predictability despite trade policy volatility. Thus, while tariffs create immediate challenges, they also accelerate structural changes in procurement practices and supply chain design across the genomics sector.

Comprehensive segmentation analysis that maps product, application, end-user, and technology dimensions to guide targeted R&D, commercialization, and service strategies

Understanding market segments is essential to shaping product development, commercial strategy, and service delivery models across the genomics domain. When the market is examined by product type, the analysis spans microarrays, PCR, reagents and consumables, sequencing services, and sequencing systems; the microarrays category further differentiates into gene expression arrays and SNP genotyping arrays, while PCR divides into digital PCR and qPCR; reagents and consumables encompass enzymes and master mixes, library preparation kits, and probes and primers; sequencing services include next-generation sequencing services and Sanger sequencing services; and sequencing systems distinguish between NGS platforms and Sanger sequencers. This product-centric view highlights where innovation is occurring and where lifecycle pressures on legacy platforms may prompt reinvestment or migration.

From an application perspective, the market covers agriculture, diagnostics, drug discovery and development, and personalized medicine. Within agriculture, the focus splits into animal genomics and crop genomics, reflecting differing sample types and analytical requirements. Diagnostics breaks down into cancer genomics, genetic testing, and infectious disease testing, each demanding distinct validation pathways and clinical workflows. Drug discovery and development emphasizes biomarker discovery and target identification, activities that rely on high-throughput, reproducible output. Personalized medicine includes companion diagnostics and precision therapeutics, areas where clinical integration and regulatory alignment are paramount.

Considering end users reveals a spectrum of organizational needs and purchasing behaviors, from academic and government institutes to commercial research organizations, hospitals and clinics, and pharmaceutical and biotechnology companies. These end users vary in procurement sophistication, throughput demands, and tolerance for operational risk. Evaluating the market through the lens of technology highlights the influence of array technology, DNA sequencing, PCR technology, and RNA sequencing. Array technology further divides into microarray gene expression and SNP genotyping arrays; DNA sequencing separates into next-generation sequencing and Sanger sequencing; PCR technology differentiates between digital PCR and qPCR; and RNA sequencing distinguishes bulk RNA sequencing from single-cell RNA sequencing. Together, these segmentation frameworks provide a comprehensive map to align R&D roadmaps, sales strategies, and service design with the nuanced needs of diverse customer cohorts.

A regional intelligence perspective that connects adoption drivers, regulatory diversity, and partnership opportunities across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics play a decisive role in determining adoption patterns, regulatory pathways, and partnership opportunities across the genomics ecosystem. In the Americas, a concentration of large academic centers, integrated healthcare systems, and an active biotechnology sector creates demand for advanced sequencing and precision diagnostics, while fostering close collaboration between commercial developers and clinical implementers. This environment encourages rapid translation of research innovations into clinical validation studies and commercial deployments.

In Europe, Middle East & Africa, the market is characterized by diversity in regulatory frameworks and healthcare delivery models, which in turn affects standardization and cross-border collaboration. The region exhibits strong capabilities in specialized research and translational initiatives, and offers unique opportunities for consortium-based projects that leverage pooled expertise and shared infrastructure. Compliance considerations and national-level reimbursement policies often shape the pace and pathway for clinical adoption.

The Asia-Pacific region demonstrates fast-paced adoption in both academic research and commercial applications, driven by investments in domestic manufacturing, growing clinical sequencing programs, and a rising base of diagnostic laboratories. Local market dynamics, including public health initiatives and agricultural genomics programs, are expanding the addressable applications for genomic technologies. Across regions, variability in reimbursement, regulatory clarity, and manufacturing capacity will continue to influence strategic entry approaches and partnership models, making regional intelligence a critical input for global planning and local execution.

How vendor strategies centered on platform integration, service expansion, and strategic partnerships are redefining competitive advantage and customer retention

Company-level behavior is shaping competitive trajectories, with leading organizations investing in platform integration, service diversification, and strategic partnerships to capture value beyond single-product sales. Firms that combine instrument innovation with robust reagent portfolios and scalable service offerings are better positioned to deliver integrated solutions that meet end-to-end customer needs. Moreover, investments in software, data analytics, and cloud-enabled interpretive services are creating new revenue streams and strengthening customer lock-in through recurring service models.

Strategic alliances and OEM relationships are increasingly common as companies seek to expand addressable markets quickly without duplicating capital expenditures. These collaborations can accelerate time to market for novel assays, enable shared risk for clinical validation, and provide complementary capabilities that enhance total solution value. Meanwhile, mid-sized players and specialized innovators continue to contribute differentiated technologies, particularly in niche applications such as single-cell analytics or novel library preparation chemistries.

Competitive positioning also hinges on operational excellence in supply chain and quality systems. Companies that demonstrate transparent manufacturing practices, robust quality management, and responsive technical support capture trust among high-stakes end users such as clinical laboratories and pharmaceutical developers. Ultimately, the most successful companies will be those that balance technological differentiation with demonstrable customer outcomes and scalable commercial models.

Practical, high-impact actions for executives to enhance supply chain resilience, enable platform interoperability, and deliver outcome-focused services that drive adoption

Industry leaders must adopt a set of actionable responses to navigate the evolving genomics environment, focusing on supply chain resilience, platform interoperability, and value-driven customer engagement. First, organizations should prioritize dual-sourcing and localized inventory strategies for critical consumables to mitigate the effects of trade policy volatility and logistics disruptions. Establishing multi-year agreements with key suppliers and investing in supplier visibility tools will reduce risk and provide operational predictability.

Second, product and services strategies should emphasize interoperability and data portability. Designing instruments and software that facilitate integration with common laboratory information systems and bioinformatics pipelines will lower barriers to adoption and increase the stickiness of commercial relationships. Equally important is an emphasis on outcome-oriented services-packaging analytical capabilities with interpretive reporting and clinical or agronomic insights will differentiate offerings in a crowded marketplace.

Finally, leaders should invest in regulatory readiness and transparent data governance practices. Proactively engaging with regulatory authorities, adopting best-practice validation protocols, and demonstrating strong data stewardship will accelerate clinical adoption and build stakeholder trust. Complementary investments in strategic partnerships, co-development agreements, and targeted regional expansion will ensure that organizations can scale responsibly while responding to localized market needs. These actions, taken together, will position industry leaders to capture long-term value despite short-term market turbulence.

A rigorous, multi-source research methodology combining primary stakeholder interviews, technical literature review, and analytical frameworks to validate trends and strategic implications

This research employed a multi-faceted methodology that combined primary stakeholder interviews, technical literature review, and systematic analysis of product and regulatory developments to ensure a comprehensive and balanced perspective. Primary engagements included conversations with R&D leaders, clinical laboratory directors, procurement specialists, and commercial leaders across instrument and reagent providers. These interactions were structured to elicit insights into operational challenges, adoption drivers, and strategic responses to evolving policy and supply chain conditions.

Secondary research involved the review of peer-reviewed journals, conference proceedings, patent filings, and public regulatory documents to validate technical trends and to trace the evolution of key technologies. Additionally, catalogues of product specifications, vendor disclosures, and publicly available case studies were synthesized to map feature differentials, integration capabilities, and deployment contexts. The methodology emphasized triangulation across sources to reduce bias and to reconcile differing perspectives on technology maturity and clinical readiness.

Analytical frameworks included segmentation mapping, scenario planning for supply chain risk, and evaluation of commercial models based on pricing, service scope, and customer support structures. Throughout, quality assurance processes were applied to check factual accuracy and to ensure that conclusions are supported by multiple independent inputs. The result is a rigorous evidence-based assessment designed to inform strategic planning and operational decision-making.

A conclusive synthesis emphasizing adaptability, technical integration, and governance as the decisive factors for sustained success in the evolving genomics ecosystem

The concluding synthesis reiterates that genomics is at an inflection point where technological capability, commercial innovation, and regulatory stewardship intersect to define future winners and laggards. Organizations that align investments in interoperable platforms, resilient supply chains, and outcome-driven services will create durable competitive advantages. Moreover, proactive engagement with regulatory and data governance issues will accelerate the translation of laboratory advances into clinical and commercial impact.

Looking ahead, the ability to translate complex data streams into actionable decisions-whether for therapeutic development, diagnostic deployment, or agricultural improvement-will distinguish high-performing organizations. Strategic partnerships, flexible business models, and a relentless focus on customer outcomes will enable firms to capture emerging opportunities while mitigating operational risks. The key message is that adaptability, technical excellence, and trustworthiness are the principal currencies in a rapidly changing genomics ecosystem.

In closing, this analysis provides a structured foundation for leaders to prioritize investments, shape product roadmaps, and refine commercial approaches. By focusing on the levers that most strongly influence adoption and value realization, organizations can navigate uncertainty and position themselves for sustainable impact in research, clinical care, and broader applied genomics contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genomics Market, by Product Type

  • 8.1. Microarrays
    • 8.1.1. Gene Expression Arrays
    • 8.1.2. SNP Genotyping Arrays
  • 8.2. PCR
    • 8.2.1. Digital PCR
    • 8.2.2. qPCR
  • 8.3. Reagents & Consumables
    • 8.3.1. Enzymes & Master Mixes
    • 8.3.2. Library Preparation Kits
    • 8.3.3. Probes & Primers
  • 8.4. Sequencing Services
    • 8.4.1. NGS Services
    • 8.4.2. Sanger Sequencing Services
  • 8.5. Sequencing Systems
    • 8.5.1. NGS Platforms
    • 8.5.2. Sanger Sequencers

9. Genomics Market, by Technology

  • 9.1. Array Technology
    • 9.1.1. Microarray Gene Expression
    • 9.1.2. SNP Genotyping Arrays
  • 9.2. DNA Sequencing
    • 9.2.1. Next-Generation Sequencing
    • 9.2.2. Sanger Sequencing
  • 9.3. PCR Technology
    • 9.3.1. Digital PCR
    • 9.3.2. qPCR
  • 9.4. RNA Sequencing
    • 9.4.1. Bulk RNA Sequencing
    • 9.4.2. Single-Cell RNA Sequencing

10. Genomics Market, by Application

  • 10.1. Agriculture
    • 10.1.1. Animal Genomics
    • 10.1.2. Crop Genomics
  • 10.2. Diagnostics
    • 10.2.1. Cancer Genomics
    • 10.2.2. Genetic Testing
    • 10.2.3. Infectious Disease Testing
  • 10.3. Drug Discovery & Development
    • 10.3.1. Biomarker Discovery
    • 10.3.2. Target Identification
  • 10.4. Personalized Medicine
    • 10.4.1. Companion Diagnostics
    • 10.4.2. Precision Therapeutics

11. Genomics Market, by End User

  • 11.1. Academic & Government Institutes
  • 11.2. Commercial Research Organizations
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Genomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Genomics Market

16. China Genomics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics, Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Azenta, Inc.
  • 17.8. BGI Genomics Co., Ltd.
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. Color Health, Inc.
  • 17.11. Eurofins Scientific SE
  • 17.12. F. Hoffmann-La Roche Ltd
  • 17.13. Fulgent Genetics, Inc.
  • 17.14. Guardant Health, Inc.
  • 17.15. Illumina, Inc.
  • 17.16. Invitae Corporation
  • 17.17. Myriad Genetics, Inc.
  • 17.18. Natera, Inc.
  • 17.19. Oxford Nanopore Technologies plc
  • 17.20. Pacific Biosciences of California, Inc.
  • 17.21. PerkinElmer, Inc.
  • 17.22. QIAGEN N.V.
  • 17.23. Thermo Fisher Scientific Inc.
  • 17.24. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. GLOBAL GENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. GCC GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. GCC GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. GCC GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 321. GCC GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 322. GCC GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 323. GCC GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 324. GCC GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 325. GCC GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 326. GCC GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. GCC GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 328. GCC GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. GCC GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 330. GCC GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. GCC GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 332. GCC GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 333. GCC GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 334. GCC GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 335. GCC GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPEAN UNION GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. EUROPEAN UNION GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPEAN UNION GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPEAN UNION GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 350. EUROPEAN UNION GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 351. EUROPEAN UNION GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 352. EUROPEAN UNION GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 353. EUROPEAN UNION GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 354. BRICS GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 355. BRICS GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. BRICS GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 357. BRICS GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 358. BRICS GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 359. BRICS GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 360. BRICS GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 361. BR